Abe Naoki, Iwata Naomi, Yasuoka Ryuhei, Nishida Daisuke, Oohara Asami, Nakaseko Haruna, Sugiura Shiro, Kawabe Shinji
Department of Allergy and Immunology, Aichi Children's Health and Medical Center, Obu, Japan.
Department of Pediatrics, Hamamatsu University School of Medicine, Shizuoka, Japan.
Pediatr Int. 2023 Jan-Dec;65(1):e15553. doi: 10.1111/ped.15553.
No previous study of Japanese children with ulcerative colitis (UC) has reported the risk factors for intolerance of 5-aminosalicylic acid (5-ASA). We aimed to identify risk factors for intolerance of oral 5-ASA preparations in pediatric UC.
Patients with childhood-onset UC who were seen at our hospital between November 2003 and March 2020 were investigated. Intolerance of 5-ASA was defined as having clinical symptoms (pyrexia, abdominal pain, diarrhea, bloody stool) that worsened after starting oral administration of 5-ASA and improved after discontinuation of 5-ASA. Patient sex, age, body size, laboratory data, pediatric UC activity index scores, and colonoscopy-based determinations of the extent and severity of the affected lesion at initiation of 5-ASA of intolerant and tolerant groups were compared.
Fifteen patients were in the intolerant group, and 37 were in the tolerant group. The leukocyte count, C-reactive protein level, and erythrocyte sedimentation rate were significantly higher in the intolerant group than the tolerant group; the albumin level in the intolerant group was significantly lower. All intolerant patients and 68% of tolerant patients had pancolitis (Paris classification E4). Patients with a large, affected area (Paris classifications E3 and E4) more frequently had intolerance to 5-ASA than patients with a small lesion. The cumulative Mayo endoscopic subscore (cMES), which is the sum of MES scores for six regions of the large intestine, was significantly higher in the intolerant group.
Pediatric UC patients with more intense inflammation and a large lesion could have an increased risk of intolerance for 5-ASA.
此前尚无针对日本溃疡性结肠炎(UC)患儿的研究报告5-氨基水杨酸(5-ASA)不耐受的风险因素。我们旨在确定儿童UC患者口服5-ASA制剂不耐受的风险因素。
对2003年11月至2020年3月期间在我院就诊的儿童期起病的UC患者进行调查。5-ASA不耐受定义为口服5-ASA后出现临床症状(发热、腹痛、腹泻、便血)加重,停用5-ASA后症状改善。比较不耐受组和耐受组患者的性别、年龄、体型、实验室数据、儿童UC活动指数评分,以及在开始使用5-ASA时基于结肠镜检查确定的受累病变范围和严重程度。
不耐受组有15例患者,耐受组有37例患者。不耐受组的白细胞计数、C反应蛋白水平和红细胞沉降率显著高于耐受组;不耐受组的白蛋白水平显著较低。所有不耐受患者和68%的耐受患者患有全结肠炎(巴黎分类E4)。与病变较小的患者相比,病变面积较大(巴黎分类E3和E4)的患者更常出现5-ASA不耐受。不耐受组的累积梅奥内镜亚评分(cMES,即大肠六个区域的MES评分总和)显著更高。
炎症更严重且病变较大的儿童UC患者可能有更高的5-ASA不耐受风险。